Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, chong K, Morton DL, Stemk-Hale K, Chen G, Noble M, Meyrson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner Sn, Hoon DSB, Shadendorf D, Lander ES, Gabriel SBl, Getz G, Garraway LA, Chin L
You know, areas that I'd focus on, still in metabolic disease but looking at things like fatty liver disease, you know, high cholesterol and then still in inflammatory disease, there's a lot of what we call unmet need, you know, a lot of folks that have psoriasis, that have, you know, various types of arthritis
For patients unable to access or tolerate Ozempic, other GLP-1 receptor agonists may be considered, including dulaglutide, liraglutide, or exenatide, though availability varies
Rat or mouse bioavailability cannot define human bioavailability
Mild symptoms such as localised itching, redness, or a small rash should be discussed with a healthcare professional as soon as possible
found that GLP-1 can reduce the levels of endogenous A in the brain and reduce the levels of APP in cultured neuronal cells (152)